Th e eff ect of single-dose etomidate on mortality in patients with sepsis remains controversial. We systematically reviewed the literature to investigate whether a single dose of etomidate for rapid sequence intubation increased mortality in patients with sepsis.
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In patients with sepsis, endotracheal intubation is a common and important procedure to secure the airway and guarantee suffi cient ventilation. However, it can lead to life-threatening complications because of the vulnerable hemodynamic status of patients with sepsis. 1 To avoid such complications, rapid sequence intubation with administration of an induction agent frequently is required. Etomidate oft en is used as an induction drug for rapid sequence intubation because it allows for a rapid, smooth, and hemodynamically stable procedure. 2 However, etomidate inhibits adrenal mitochondrial 11-b -hydroxylase activity and can cause reversible adrenal insuffi ciency, 3, 4 which may restrict its use in patients with sepsis who are prone to relative adrenal insuffi ciency. 5 Although there is no controversy about etomidate causing adrenal insuffi ciency, the eff ect of etomidate on mortality in sepsis remains an issue. 6 So far, studies reporting the eff ect of etomidate on mortality in sepsis have conveyed confl icting results. Furthermore, due to small sample sizes, these studies were not adequately powered to detect the eff ect of etomidate on mortality in patients with sepsis. Th us, to provide the latest and most convincing evidence, we systematically reviewed the current available literature to investigate whether single-dose etomidate increases mortality in patients with sepsis. Th e secondary objective was to evaluate the eff ect of single-dose etomidate on adrenal insuffi ciency, length of hospital and ICU stay, and duration of mechanical ventilation (MV).
Materials and Methods

Literature Search and Selection Criteria
Th is systematic review and meta-analysis was conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). 7 PubMed, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched for records reporting the eff ect of single-dose etomidate on mortality in patients with sepsis. Th e search strategy is shown in Table 1 . No language restriction was imposed. Th e last search was run on July 16, 2014 . Two independent investigators carried out the initial search, deleted duplicate records, screened the titles and abstracts for relevance, and identifi ed each as excluded or requiring further assessment. We reviewed the full-text articles designated for inclusion and manually checked the references of the retrieved articles and previous reviews to identify additional eligible studies.
Studies meeting the following criteria were included: (1) population: adult patients with sepsis, severe sepsis, or septic shock; (2) intervention: single-dose etomidate; (3) comparison: other sedatives or no agent; (4) outcome: mortality (either hospital or 28-day); and (5) design: randomized controlled trials (RCTs) and observational studies (prospective or retrospective cohort studies). Agreement regarding study inclusion was assessed using the Cohen k statistic. 8 
Data Extraction and Quality Assessment
Data extraction was performed by L. T. and confi rmed independently by F. W. Th e following information was extracted from each study: fi rst author, year of publication, country, study design, patient characteristics, number of patients enrolled, intervention, and outcome data (mortality, adrenal insuffi ciency, length of hospital stay, length of ICU stay, and duration of MV). When the same patients were reported in several publications, we retained only the largest study to avoid duplication of information. Extracted data were entered into a standardized Excel (Microsoft Corporation) file. Discrepancies were resolved by discussion between the two investigators. The primary outcome was all-cause mortality. Secondary outcomes were adrenal insufficiency, length of hospital and ICU stay, and duration of MV. Th e Cochrane risk of bias tool was adopted to assess the risk of bias for each RCT. 9 Observational studies were evaluated using the Newcastle-Ottawa Scale. 10 
Statistical Analysis
Data were analyzed separately for RCTs and observational studies. Differences were expressed as relative risk (RR) with 95% CI. Heterogeneity across studies was tested with the I 2 statistic, which is a quantitative measure of inconsistency across studies. Studies with an I 2 statistic of 25% to 50% were considered to have low heterogeneity, those with an I 2 statistic of 50% to 75% were considered to have moderate heterogeneity, and those with an I 2 statistic of . 75% were considered to have high heterogeneity. I 2 . 50% indicates signifi cant heterogeneity. 11 Th e Mantel-Haenszel method with random-eff ects modeling was used to calculate pooled RRs and 95% CIs.
Post hoc analysis of RCTs was considered equivalent to observational studies. In addition, subgroup analyses for observational studies were conducted according to study design (post hoc analysis of RCTs vs cohort studies), population (sepsis vs severe sepsis or septic shock), setting (single center vs multicenter), mortality end point (28-day vs hospital), sample size ( Ն 500 vs , 500), and region (North America vs Europe vs Asia). Th e subgroup analyses were performed only for mortality due to small numbers of studies for other outcomes. We also investigated the infl uence of a single study on the overall pooled estimate by omitting one study in each turn for observational studies.
Publication bias was assessed by visually inspecting a funnel plot in which the log RRs were plotted against their SEs. Th e presence of publication bias was also evaluated by using the Begg and Egger tests. 12,13 P , .05 was considered statistically significant, except where otherwise specifi ed. All statistical analyses were performed using Stata 12.0 (StataCorp LP) and RevMan 5.2 (Nordic Cochrane Centre).
Results
Study Identifi cation and Selection
A total of 424 records were identifi ed from the initial database search. Ninety-eight records were excluded for duplicates, and 306 records were excluded for various reasons based on the titles and abstracts (reviews, letters, animal studies, or irrelevant to the analysis). Th e remaining 20 full-text articles were assessed for eligibility, and two were excluded because they focused on children. 14, 15 Finally, 18 studies were included in the meta-analysis. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Th e selection process is shown in Figure 1 . Th e Cohen k statistic for agreement on study inclusion was 0.91. 
Study Characteristics
Th e main characteristics of the included studies are shown in Table 2 , and the outcome data of each included study are shown in 16, 18, 19, 22, 23, 29 and two in Asia. 20, 24 Seven studies were multicenter studies. 16, 18, 19, 28, [30] [31] [32] All studies were published in English. Etomidate was compared with midazolam in two studies 17, 24 and with ketamine in one study, 16 and the other studies did not specify the comparative sedatives. [18] [19] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] [31] [32] [33] Th e subject population varied across studies as follows: Six included patients with sepsis, 16, 17, 25, 26, 30, 32 nine included patients with septic shock, [18] [19] [20] [21] [22] [23] 29, 31, 33 and three included patients with severe sepsis and septic shock. 24, 27, 28 Five studies provided adjusted RRs for mortality, accounting for confounders. 19, 27, [29] [30] [31] Quality Assessment
Risk of bias assessment of the included studies is presented in Tables 4 and 5 . Both RCTs 16,17 generated an adequately randomized sequence, were conducted in a blinded fashion, reported the numbers and reasons for withdrawal or dropout, and were free of other bias. Th e allocation sequence concealment was not reported in the study by Tekwani et al. 17 Based on the NewcastleOttawa Scale to assess the risk of bias of the cohort studies, 10 studies [19] [20] [21] [22] [23] [25] [26] [27] 29, 32 were rated as a total score of . 5 and fi ve studies 24, 28, 30, 31, 33 as a score of Յ 5, indicating a high risk of bias. Table 6 .
Secondary Outcomes
Eight of the included studies provided data for adrenal insuffi ciency. 16, 18, 19, 21, 23, 24, 27, 31 Single-dose etomidate increased the risk of adrenal insuffi ciency in patients with sepsis (RR, 1.42; 95% CI, 1.22-1.64; P , .00001) ( Fig 3 ) . Table 3 outlines data of length of hospital stay, length of ICU stay, and duration of MV. Original publications suggested that single-dose etomidate had no eff ects on these outcomes. Due to limited available data, pooled analyses for these outcomes were not conducted.
Publication Bias
For the meta-analysis of single-dose etomidate on all-cause mortality, there was no evidence of signifi cant publication bias by inspection of the funnel plot and formal statistical tests (Egger test, P 5 .917; Begg test, P 5 .363) ( Fig 4 ) .
Discussion
Main Finding
Th e present systematic review and meta-analysis identifi ed two RCTs and 16 observational studies investigating the eff ect of single-dose etomidate for rapid sequence intubation on mortality in patients with sepsis. Th e analysis showed that single-dose etomidate did not increase mortality in patients with sepsis, both in RCTs and in observational studies. Moreover, these fi ndings were consistent across adjusted analyses, in the infl uence analysis, and across all subgroup analyses for observational studies. Risk of bias was assessed using the Cochrane risk of bias tool. Risk of bias was assessed using the Newcastle-Ottawa Scale. A higher overall score corresponds to a lower risk of bias; a score of Յ 5 (out of 9) indicates a high risk of bias.
Comparison With Previous Studies
Diff erences between the current meta-analysis and previous meta-analyses should be noted. A meta-analysis by Chan et al 34 included one prospective cohort study 26 and four "RCTs" 16, 17, 19, 20 in 865 patients and concluded that single-dose etomidate was associated with an increased mortality in patients with sepsis. Of note, two included studies 19, 20 were not RCTs but rather post hoc analyses of RCTs. It may be improper to directly consider these two studies as RCTs. In another meta-analysis focusing on critically ill patients, Albert et al 35 also concluded that single-dose etomidate was associated with an increased mortality in patients with sepsis. Th e result was based on a subgroup analysis of seven studies and an improper fi xed-eff ects model of Mantel-Haenszel due to signifi cant heterogeneity ( I 2 5 75%). If adopting an appropriate random-eff ects model, no signifi cant association is detected between single-dose etomidate and mortality in patients with sepsis (RR, 1.12; 95% CI, 0.91-1.38; P 5 .29). Overall, both previous meta-analyses had obvious fl aws that might threaten the authenticity of their fi ndings. Aft er the two meta-analyses, several studies investigating single-dose etomidate in patients with sepsis were published. Th e present updated metaanalysis included 18 studies in 5,552 patients, and the data were from RCTs, post hoc analyses of RCTs, and prospective and retrospective cohort studies. In contrast with the previous meta-analyses, the present one suggests that single-dose etomidate is not associated with an increased mortality in patients with sepsis. Moreover, adjusted analyses, infl uence analysis, and all subgroup analyses for observational studies did not materially alter the pooled result, which added robustness to the main fi ndings. It is well-known that etomidate suppresses adrenal steroidogenesis for at least 24 to 48 h through the inhibition of 11-b -hydroxylase, even aft er a single dose. 3 In a retrospective study of 152 patients with septic shock, the incidence of an inadequate response to corticotropin in patients receiving etomidate was signifi cantly higher than in those who had not received etomidate (76% vs 51%, P , .01). 21 Consistent with the meta-analysis by Chan et al, 34 the present one also suggests that singledose etomidate for intubation was associated with a higher risk of adrenal insuffi ciency in patients with sepsis. It would be logical for clinicians to assume that concurrent administration of corticosteroids could counterbalance this eff ect. However, supplementing hydrocortisone to compensate for the adrenal-suppressive eff ects of single-dose etomidate on outcomes did not seem to work, as shown in a subanalysis of the Corticosteroid Th erapy of Septic Shock (CORTICUS) study wherein concurrent hydrocortisone administration did not change the mortality of patients with septic shock (45% vs 40%). 19 An RCT was conducted to specifically address this question for critically ill patients. 36 Aft er single-dose etomidate for endotracheal intubation, patients were randomized to receive a 42-h continuous infusion of hydrocortisone 200 mg/d or saline, and no signifi cant diff erence in 28-day mortality was detected.
A prospective study by Molenaar et al 37 demonstrated that single-dose etomidate may attenuate stimulated more than basal cortisol synthesis and only partly contribute to adrenal dysfunction in the stressed patient with sepsis. Concurrent administration of opioids and benzodiazepines in these patients could induce adrenal insuffi ciency because of reduced secretion of adrenocorticotropic hormone. 38 Considering that adrenal insufficiency might be a predictor of mortality in patients with sepsis, 39 it was reasonable to infer that hydrocortisone therapy might improve survival of these patients. However, the latest meta-analysis of RCTs demonstrated that low-dose hydrocortisone therapy did not reduce 28-day mortality in patients with septic shock, although it attenuated septic shock at 7 and 28 days. 40 Consequently, corticosteroids should be reserved for refractory shock independent of etomidate use in patients with sepsis. In this context, the effi cacy of corticosteroids may be related to enhancing the hemodynamic response to norepinephrine rather than to mitigating etomidate-related 11-b -hydroxylase inhibition.
Several potential limitations should be taken into consideration when interpreting the present results. First, among the 18 included studies, only two were small RCTs, whereas the other 16 were observational studies. Observational studies are highly subject to selection bias and confounding by indication. Of the observational studies included in the present meta-analysis, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 10 reported no signifi cant diff erence in the baseline characteristics between the etomidate and control groups, 18, [20] [21] [22] [23] [24] [25] [26] 28, 33 one used propensity-matched analysis to compare the etomidate and control groups, 32 and the remaining fi ve provided adjusted RRs to account for confounders. 19, 27, [29] [30] [31] Second, although no signifi cant heterogeneity was found for the primary outcome, population characteristics, severity of illness, and type of comparative sedatives varied across the included studies. To examine the infl uence of these clinical factors on the overall pooled estimate and to verify the robustness of the fi ndings, subgroup analyses were conducted and the results found consistent, which added robustness. Th ird, we were unable to assess the impact of single-dose etomidate on other clinically meaningful end points, such as length of hospital stay, length of ICU stay, and duration of MV, due to sparse and inconsistent reporting across studies.
In conclusion, the present systematic review and metaanalysis suggests that single-dose etomidate is not associated increased mortality in patients with sepsis. Etomidate may remain an acceptable option for rapid sequence intubation in patients with sepsis; however, the fi nding largely relies on data from observational studies, is potentially subject to selection bias, and should be interpreted cautiously. Hence, high-quality and adequately powered RCTs are warranted.
